Grifols (GIFLF) Receivables (2009 - 2025)
Grifols' (GIFLF) quarterly Receivables came in at $875.4 million in Q4 2025, up 4.62% on a YoY basis from $836.7 million in Q4 2024, and up 4.62% quarter-over-quarter from $836.7 million in Q4 2024.
Analysis
Grifols (GIFLF) Receivables (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Receivables for 17 consecutive years, with $875.4 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Receivables rose 4.62% year-over-year to $875.4 million; the trailing twelve-month figure through Dec 2025 stood at $875.4 million (up 4.62% YoY), and the FY2025 full-year result was $849.6 million, down 2.98% from the prior year.
- Receivables improved to $875.4 million in Q4 2025 per GIFLF's latest filing, from $836.7 million in the prior quarter.
- Across five years, Receivables topped out at $875.4 million in Q4 2025 and bottomed at $53.7 million in Q4 2023.
- Historically, Receivables has averaged $604.3 million across 5 years, with a median of $696.1 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Receivables sank 92.28% in 2023, then jumped 1457.4% in 2024.
- Over 5 years, Receivables stood at $559.6 million in 2021, then grew by 24.38% to $696.1 million in 2022, then tumbled by 92.28% to $53.7 million in 2023, then surged by 1457.4% to $836.7 million in 2024, then climbed by 4.62% to $875.4 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $875.4 million, $836.7 million, and $53.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 875.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 875.36 Mn |
| Dec 31, 2024 | 836.71 Mn |
| Dec 31, 2023 | 53.72 Mn |
| Dec 31, 2022 | 696.08 Mn |
| Dec 31, 2021 | 559.63 Mn |
| Dec 31, 2020 | 543.20 Mn |
| Sep 30, 2020 | 663.81 Mn |
| Mar 31, 2020 | 560.38 Mn |
| Dec 31, 2019 | 500.65 Mn |
| Sep 30, 2019 | 516.62 Mn |
| Mar 31, 2019 | 678.24 Mn |
| Dec 31, 2018 | 412.71 Mn |
| Sep 30, 2018 | 538.34 Mn |
| Jun 30, 2018 | 464.64 Mn |
| Mar 31, 2018 | 496.64 Mn |
| Dec 31, 2017 | 384.88 Mn |
| Jun 30, 2017 | 429.83 Mn |
| Dec 31, 2016 | 492.31 Mn |
| Sep 30, 2016 | 482.23 Mn |
| Jun 30, 2016 | 561.65 Mn |